Hutchmed (HKG:0013) is weighing its supply chain options for blood cancer drug, tazemetostat, amid the impact of US tariffs against China, the South China Morning Post reported Monday, citing chief executive and scientific officer Su Weiguo.
China's medical products administrator in March approved tazemetostat for follicular-lymphoma patients with an EZH2 mutation and who have not responded to treatment or those who have recurrent cancer.
Because tazemetostat is currently made in the US, it could be subjected to tariffs should it be imported into China, the report said.
Should the impact of tariffs be substantial, Hutchmed may look to manufacture the anti-cancer drug in Europe or China, Su reportedly said.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。